Celsion Co. (NASDAQ:CLSN – Get Rating) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 195,300 shares, a growth of 236.1% from the March 31st total of 58,100 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average trading volume of 315,600 shares, the days-to-cover ratio is presently 0.6 days.
Shares of CLSN opened at $3.05 on Thursday. The company has a market cap of $17.60 million, a PE ratio of -0.78 and a beta of 2.11. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 0.10. The stock has a 50-day moving average price of $4.67 and a 200-day moving average price of $8.11. Celsion has a 12-month low of $2.97 and a 12-month high of $23.25.
CLSN has been the topic of a number of research reports. StockNews.com started coverage on Celsion in a report on Wednesday. They issued a “hold” rating on the stock. HC Wainwright started coverage on Celsion in a research note on Wednesday, April 13th. They set a “buy” rating and a $16.00 target price for the company.
Celsion Company Profile (Get Rating)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
- Get a free copy of the StockNews.com research report on Celsion (CLSN)
- Automatic Data Processing Is Ready To Scale New Heights
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.